top of page

Content Rheum

Interleukin-17 Inhibition

FAQs

Click a title to watch the FAQ

Describe the IL17-Induced inflammatory cascade.

Provide immunologic rationale for IL17-directed therapy in PsA, AS, and nr-axSpA.

How do you explain the timing of ixekizumab's clinical efficacy to patients?

Are IL-17 inhibitors efficacious in treating the nail-DIP complex in PsA?

Can you recapture response to IL-17i therapy after an interruption or discontinuation in therapy?

Medication Review_v2.png

MEDICATION REVIEWS

Click a title to watch the review

Describe the mechanism of action of ixekizumab.

What is the safety profile of ixekizumab in PsA and axSpA?

What is the efficacy of ixekizumab across the GRAPPA & EULAR domains?

JOURNAL CLUBS

Click a title to watch the journal club

Safety of ixekizumab with or without methotrexate in biologic-naïve patients with psoriatic arthritis: 52-week results from SPIRIT-H2H study.

A head-to-head comparison of ixekizumab vs. guselkumab in patients with moderate-to-severe plaque psoriasis: 12-week efficacy, safety and speed of response from a randomized, double-blinded trial.

PODCASTS

Click a title to watch the podcast

RhAPPcast: Navigating the Complexities: IL-17 inhibitors and IBD risk

RhAPPcast: Decoding IL-17: Comparing and contrasting IL-17A and IL-17F inhibition

Become a RhAPP Member

bottom of page